J Gen Virol Tips for Better Browsing
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Gen Virol 88 (2007), 814-822; DOI 10.1099/vir.0.82503-0

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Naucler, P.
Right arrow Articles by Chen, C.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Naucler, P.
Right arrow Articles by Chen, C.-J.
Agricola
Right arrow Articles by Naucler, P.
Right arrow Articles by Chen, C.-J.

Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case–control study

Pontus Naucler1, Hui-Chi Chen2, Kenneth Persson1, San-Lin You2, Chang-Yao Hsieh2, Chien-An Sun3, Joakim Dillner1 and Chien-Jen Chen2

1 Lund University, University Hospital at Malmö, SE-20502 Malmö, Sweden
2 National Taiwan University, Taipei, Taiwan
3 National Defence Medical Center, Taipei, Taiwan

Correspondence
Joakim Dillner
joakim.dillner{at}med.lu.se

A nested case–control study of invasive and in situ cervical cancer was performed within a community-based cohort of 13 595 Taiwanese women assembled in 1991, with a follow-up period of 9 years. Baseline serum or plasma samples were analysed for antibodies against human papillomavirus (HPV) types 6, 16 and 18 and Chlamydia trachomatis. In total, 114 cases (42 incident cases identified during follow-up and 72 prevalent cases identified at baseline) and 519 matched controls were included in the study. HPV-16 seropositivity was strongly associated with cervical cancer (OR=6.33; 95 % CI 3.45–11.62). Overall, C. trachomatis was not associated with cervical cancer, but was associated with cervical cancer in analyses restricted to incident cases of cancer (OR=2.94; 95 % CI 1.17–7.42) or to cases in which serum samples were analysed (OR=3.13; 95 % CI 1.16–8.47). An antagonistic interaction between HPV-6 and -16 was found in a multiplicative model. These results suggest that different HPV types might interfere in cervical carcinogenesis and that C. trachomatis is associated with cervical cancer in prospective studies, and support the notion that HPV-16 seropositivity is strongly associated with cervical cancer.




This article has been cited by other articles:


Home page
CVIHome page
S. Gorander, T. Lagergard, M. Romanik, R. P. Viscidi, G. Martirosian, and J.-A. Liljeqvist
Seroprevalences of Herpes Simplex Virus Type 2, Five Oncogenic Human Papillomaviruses, and Chlamydia trachomatis in Katowice, Poland
Clin. Vaccine Immunol., April 1, 2008; 15(4): 675 - 680.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS
Copyright © 2007 by the Society for General Microbiology.